Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $885000.0.

  • Aytu Biopharma's Depreciation & Amortization (CF) fell 3150.15% to $885000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $4.4 million, marking a year-over-year decrease of 2235.44%. This contributed to the annual value of $5.4 million for FY2025, which is 2004.46% down from last year.
  • As of Q4 2025, Aytu Biopharma's Depreciation & Amortization (CF) stood at $885000.0, which was down 3150.15% from $803000.0 recorded in Q3 2025.
  • Aytu Biopharma's 5-year Depreciation & Amortization (CF) high stood at $3.3 million for Q2 2021, and its period low was $803000.0 during Q3 2025.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $2.0 million (2021), whereas its average is $1.9 million.
  • As far as peak fluctuations go, Aytu Biopharma's Depreciation & Amortization (CF) skyrocketed by 7184.76% in 2021, and later plummeted by 4017.94% in 2024.
  • Aytu Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $2.7 million in 2021, then decreased by 17.53% to $2.2 million in 2022, then dropped by 18.81% to $1.8 million in 2023, then dropped by 27.86% to $1.3 million in 2024, then plummeted by 31.5% to $885000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $885000.0 in Q4 2025, compared to $803000.0 in Q3 2025 and $1.3 million in Q2 2025.